Drugs / LYT-200
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05829226 | Dec 2022 → Dec 2025 | acute myeloid leukemia, myelodysplastic syndrome | PureTech | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04666688 | Dec 2020 → Dec 2024 | colorectal cancer, head and neck cancer, malignant pancreatic neoplasm, metastatic malignant neoplasm +1 | PureTech | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LYT-200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05829226 ↗ |
| Modality | Monoclonal antibody | “monoclonal antibody (mAb), targeting galectin-9 protein” NCT04666688 ↗ |
| Route | Intravenous | “administered via IV infusion over 60 minutes every week” NCT05829226 ↗ |